2025. A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes. Reumatismo. (May 2025). DOI:https://doi.org/10.4081/reumatismo.2025.1748.